Full Text Journal Articles by
Author Surena F Matin

Advertisement

Find full text journal articles






Editorial Comment.

Tanner S Miest, Surena F Matin,

J Urol (The Journal of urology)
[2021, :101097JU000000000000178602]

Cited: 0 times

View full text PDF listing >>



Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study.

Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Gautier Marcq, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Wassim Kassouf, Riccardo Autorino, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat,

<h4>Background</h4>Several groups have proposed features to identify low-risk patients who may benefit from endoscopic kidney-sparing surgery in upper tract urothelial carcinoma (UTUC).<h4>Objective</h4>To evaluate standard risk stratification features, develop an optimal model to identify ≥pT2/N+ stage at radical nephroureterectomy (RNU), and compare it with the existing unvalidated models.<h4>Design, setting, and participants</h4>This ... Read more >>

Eur Urol (European urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma.

Firas G Petros, Woonyoung Choi, Yuan Qi, Tyler Moss, Roger Li, Xiaoping Su, Charles C Guo, Bogdan Czerniak, Colin Dinney, David J McConkey, Surena F Matin,

<h4>Purpose</h4>We compared upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) in same-patient metachronous UTUC and synchronous UTUC and BUC using next-generation sequencing.<h4>Materials and methods</h4>Consecutive untreated same-patient samples of UTUC and BUC were macrodissected from unstained formalin-fixed, paraffin-embedded slides after quality control. Samples were divided into 4 groups: 1) ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001788]

Cited: 0 times

View full text PDF listing >>



Outcomes of Percutaneous Thermal Ablation for Biopsy-Proven T1a Renal Cell Carcinoma in Patients With Other Primary Malignancies.

Mohamed E Abdelsalam, Sharjeel H Sabir, Samuel B Kusin Ba, Jose A Karam, Surena F Matin, Christopher G Wood, Kamran Ahrar,

<b>OBJECTIVE.</b> The purpose of this article is to investigate the oncologic effectiveness and survival outcomes of percutaneous image-guided thermal ablation for clinical T1a renal cell carcinoma (RCC) in patients with other primary nonrenal malignancies. <b>METHODS.</b> We reviewed records of patients with histologically proven T1a RCC (< 4.0 cm) treated with ... Read more >>

AJR Am J Roentgenol (AJR. American journal of roentgenology)
[2021, :1-7]

Cited: 0 times

View full text PDF listing >>



The Impact of Upper Tract Urothelial Carcinoma Diagnostic Modality on Intravesical Recurrence after Radical Nephroureterectomy: A Single Institution Series and Updated meta-Analysis.

Vidit Sharma, Tanner S Miest, Tristan S Juvet, Amir Toussi, Vignesh Packiam, Karim Chamie, Surena F Matin, Stephen A Boorjian, R Houston Thompson, Igor Frank, Matthew K Tollefson, Aaron M Potretzke,

<h4>Introduction</h4>Diagnostic ureteroscopic biopsy for upper tract urothelial carcinoma (UTUC) has been hypothesized to increase intravesical recurrence of urothelial carcinoma after radical nephroureterectomy (RNU). Moreover, the impact of ureteroscopy without biopsy or percutaneous biopsy on intravesical recurrence remains unknown. Herein, we compared post-RNU intravesical recurrences across UTUC diagnostic modalities.<h4>Methods</h4>Patients undergoing RNU ... Read more >>

J Urol (The Journal of urology)
[2021, :101097JU0000000000001834]

Cited: 0 times

View full text PDF listing >>



Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk-stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study.

Gautier Marcq, Beat Foerster, Mohammad Abufaraj, Surena F Matin, Mounsif Azizi, Mohit Gupta, Wei-Ming Li, Thomas Seisen, Timothy Clinton, Evanguelos Xylinas, M Carmen Mir, Donald Schweitzer, Andrea Mari, Shoji Kimura, Marco Bandini, Romain Mathieu, Ja H Ku, Georgi Guruli, Markus Grabbert, Anna K Czech, Tim Muilwijk, Armin Pycha, David D'Andrea, Firas G Petros, Philippe E Spiess, Trinity Bivalacqua, Wen-Jeng Wu, Morgan Rouprêt, Laura-Maria Krabbe, Kees Hendricksen, Shin Egawa, Alberto Briganti, Marco Moschini, Vivien Graffeille, Riccardo Autorino, Patricia John, Axel Heidenreich, Piotr Chlosta, Steven Joniau, Francesco Soria, Phillip M Pierorazio, Shahrokh F Shariat, Wassim Kassouf,

<h4>Background</h4>The European Association of Urology risk stratification dichotomizes patients with upper tract urothelial carcinoma (UTUC) into two risk categories.<h4>Objective</h4>To evaluate the predictive value of a new classification to better risk stratify patients eligible for kidney-sparing surgery (KSS).<h4>Design, setting, and participants</h4>This was a retrospective study including 1214 patients from 21 centers ... Read more >>

Eur Urol Focus (European urology focus)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Therapeutic Consequences of Omitting a Pelvic Lymph Node Dissection at Radical Prostatectomy when Grade and/or Stage Increase.

Muammer Altok, Brian F Chapin, Surena F Matin, Mary F Achim, Justin R Gregg, John W Davis,

<h4>Objective</h4>To analyze the effect on biochemical recurrence (BCR) of omitting PLND in subsequently upgraded/upstaged patients (pNx regret). Using nomograms, patients with low to intermediate-risk prostate cancer can be selected to omit a pelvic lymph node dissection (PLND) at the time of a radical prostatectomy (RP). However, some patients will experience ... Read more >>

Urology (Urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer.

Kelly K Bree, Patrick J Hensley, Nathan A Brooks, Justin Matulay, Roger Li, Graciela M Nogueras Gonzalez, Neema Navai, Herbert Barton Grossman, Surena F Matin, Colin P N Dinney, Ashish M Kamat,

<h4>Objective</h4>To evaluate the impact of upper tract urothelial carcinoma (UTUC) on bacillus Calmette-Guerin (BCG) response and progression in patients with non-muscle-invasive bladder cancer (NMIBC).<h4>Patients and methods</h4>We performed an institutional review board-approved review of patients with NMIBC treated with adequate intravesical BCG, as defined by the US Food and Drug Administration, ... Read more >>

BJU Int (BJU international)
[2021, :]

Cited: 1 time

View full text PDF listing >>



Editorial Comment.

Mehrad Adibi, Surena F Matin,

J Urol (The Journal of urology)
[2021, 205(4):1046]

Cited: 0 times

View full text PDF listing >>



Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy.

John P Sfakianos, Zeynep Gul, Shahrokh F Shariat, Surena F Matin, Siamak Daneshmand, Elizabeth Plimack, Seth Lerner, Morgan Roupret, Sumanta Pal,

<h4>Context</h4>Bladder urothelial carcinoma (BUC) and upper tract urothelial carcinoma (UTUC) have genetic differences, which may influence therapy.<h4>Objective</h4>The aim of the current review was to summarize the current genetic understanding of upper tract and BUC.<h4>Evidence acquisition</h4>PubMed, Cochrane, and Web of Science online databases were searched systematically up to February 2020, using ... Read more >>

Eur Urol Oncol (European urology oncology)
[2021, 4(2):170-179]

Cited: 1 time

View full text PDF listing >>



Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors.

Jad Chahoud, Pavlos Msaouel, Jeremy A Ross, Barrett Z McCormick, Tharakeswara K Bathala, Jianjun Gao, Robert Horn, Lianchun Xiao, Kanishka Sircar, Matthew T Campbell, Amishi Y Shah, Sangeeta Goswami, Amado J Zurita, Eric Jonasch, Surena F Matin, Christopher G Wood, Jose A Karam, Padmanee Sharma, Nizar M Tannir,

<h4>Introduction</h4>Metastatic renal cell carcinoma with sarcomatoid dedifferentiation (sRCC) is associated with poor survival outcomes. We aimed to analyze the efficacy and safety of immune checkpoint inhibitors (ICI) in patients with sRCC comparing clear-cell (sccRCC) to non-clear cell epithelial histology (snccRCC).<h4>Methods</h4>We performed retrospective analysis of sRCC patients who received ICI at ... Read more >>

Urol Oncol (Urologic oncology)
[2021, 39(2):134.e9-134.e16]

Cited: 0 times

View full text PDF listing >>



EDITORIAL COMMENT.

Kelly Bree, Surena F Matin,

Urology (Urology)
[2020, 145:171]

Cited: 0 times

View full text PDF listing >>



Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.

Jianjun Gao, Neema Navai, Omar Alhalabi, Arlene Siefker-Radtke, Matthew T Campbell, Rebecca Slack Tidwell, Charles C Guo, Ashish M Kamat, Surena F Matin, John C Araujo, Amishi Y Shah, Pavlos Msaouel, Paul Corn, Jianbo Wang, John N Papadopoulos, Shalini S Yadav, Jorge M Blando, Fei Duan, Sreyashi Basu, Wenbin Liu, Yu Shen, Yuwei Zhang, Marc Daniel Macaluso, Ying Wang, Jianfeng Chen, Jianhua Zhang, Andrew Futreal, Colin Dinney, James P Allison, Sangeeta Goswami, Padmanee Sharma,

Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with localized urothelial carcinoma<sup>1,2</sup>, with one study reporting data in cisplatin-ineligible patients who received anti-PD-L1 monotherapy<sup>2</sup>. The study reported that patients with bulky tumors, a known high-risk feature defined as greater than clinical T2 disease, had fewer responses, ... Read more >>

Nat Med (Nature medicine)
[2020, 26(12):1845-1851]

Cited: 4 times

View full text PDF listing >>



Survival following cytoreductive nephrectomy: a comparison of existing prognostic models.

Mary E Westerman, Daniel D Shapiro, Nizar M Tannir, Matthew T Campbell, Surena F Matin, Jose A Karam, Christopher G Wood,

<h4>Objective</h4>To validate models currently used to predict metastatic renal cell carcinoma (mRCC) outcomes in a cohort of patients undergoing cytoreductive nephrectomy (CN).<h4>Patients and methods</h4>A total of 10 RCC prognostic models (International Metastatic RCC Database Consortium [IMDC]; Memorial Sloan Kettering Cancer Center [MSKCC]; Culp; Leibovich; University of California at Los Angeles ... Read more >>

BJU Int (BJU international)
[2020, 126(6):745-753]

Cited: 1 time

View full text PDF listing >>



Comparison of the Comprehensive Complication Index and Clavien-Dindo systems in predicting perioperative outcomes following radical nephroureterectomy.

Scott Geiger, Neil Kocher, Dan Illinsky, Evanguelos Xylinas, Peter Chang, Lauren Dewey, Andrew A Wagner, Firas Petros, Surena F Matin, Conrad Tobert, Chad Tracy, Pierre-Marie Patard, Mathieu Roumiguie, Leonardo Lima Monteiro, Wassim Kassouf, Jay D Raman,

<h4>Background</h4>Complications can occur following radical nephroureterectomy (RNU) in 20-40% of patients. The Comprehensive Complication Index (CCI) is an alternative grading system to the Clavien-Dindo (CD) grading system that aggregates all complications experienced by a patient on a continuous (as opposed to categorical) scale. We investigate whether the cumulative nature of ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2020, 9(4):1780-1785]

Cited: 1 time

View full text PDF listing >>



Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy.

Andrew G McIntosh, Eric C Umbreit, Levi C Holland, Cindy Gu, Nizar M Tannir, Surena F Matin, Jose A Karam, Stephen H Culp, Christopher G Wood,

<h4>Background</h4>The management of metastatic renal cell carcinoma (mRCC) has evolved rapidly, and results from the Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial bring into question the utility of cytoreductive nephrectomy (CN). The objective of this study was to examine overall survival (OS) and identify risk factors associated with ... Read more >>

Cancer (Cancer)
[2020, 126(17):3950-3960]

Cited: 2 times

View full text PDF listing >>



Reply by Authors.

Daniel M Geynisman, Brian T Kadow, Brian M Shuch, Stephen A Boorjian, Surena F Matin, Edward Rampersaud, Barton N Milestone, Elizabeth R Plimack, Matthew R Zibelman, Alexander Kutikov, Marc C Smaldone, David Yt Chen, Rosalia Viterbo, Shreyas Joshi, Richard E Greenberg, Lois Malizzia, Thomas McGowan, Eric A Ross, Robert G Uzzo,

J Urol (The Journal of urology)
[2020, 204(3):536-537]

Cited: 0 times

View full text PDF listing >>



Molecular Characterization of Upper Tract Urothelial Carcinoma in the Era of Next-generation Sequencing: A Systematic Review of the Current Literature.

Melanie R Hassler, Freddie Bray, James W F Catto, Arthur P Grollman, Arndt Hartmann, Vitaly Margulis, Surena F Matin, Morgan Roupret, John P Sfakianos, Shahrokh F Shariat, Bishoy M Faltas,

<h4>Context</h4>While upper tract urothelial carcinoma (UTUC) share histological appearance with bladder cancer (BC), the former has differences in etiology and clinical phenotype consistent with characteristic molecular alterations.<h4>Objective</h4>To systematically evaluate current genomic sequencing and proteomic data examining molecular alterations in UTUC.<h4>Evidence acquisition</h4>A systematic review using PubMed, Scopus, and Web of Science ... Read more >>

Eur Urol (European urology)
[2020, 78(2):209-220]

Cited: 8 times

View full text PDF listing >>



Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.

Yuval Freifeld, Rashed Ghandour, Nirmish Singla, Solomon Woldu, Aditya Bagrodia, Yair Lotan, Leonid M Rapoport, Magomet Gazimiev, Karen Delafuente, Rohan Kulangara, Haley Robyak, Firas G Petros, Jay D Raman, Surena F Matin, Vitaly Margulis,

<h4>Purpose</h4>Single, postoperative instillation of prophylactic intravesical chemotherapy (pIVC) is effective in reducing bladder cancer recurrences following radical nephroureterectomy (RNU). Despite high level evidence, pIVC is underutilized. Intraoperative pIVC (I-pIVC) may be easier and safer to implement than postoperative pIVC (P-pIVC). We aimed to evaluate the efficacy of I-pIVC during RNU.<h4>Materials ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(9):737.e11-737.e16]

Cited: 0 times

View full text PDF listing >>



UGN-101 (mitomycin gel): a novel treatment for low-grade upper tract urothelial carcinoma.

Andrea Kokorovic, Surena F Matin,

Upper tract urothelial carcinoma (UTUC) is a rare malignancy. The standard treatment for localized high-risk disease is radical nephroureterectomy, which confers significant morbidity and is not appropriate for all patients. Patients harboring low-risk, non-invasive disease may be candidates for organ-sparing treatment, which includes endoscopic resection with or without intracavitary drug ... Read more >>

Ther Adv Med Oncol (Therapeutic advances in medical oncology)
[2020, 12:1758835920937950]

Cited: 0 times

View full text PDF listing >>



Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma.

Nirmish Singla, Alana Christie, Yuval Freifeld, Rashed A Ghandour, Solomon L Woldu, Timothy N Clinton, Firas G Petros, Haley Robyak, Hsin-Chih Yeh, Dong Fang, Dmitry Enikeev, Aditya Bagrodia, Arthur I Sagalowsky, Yair Lotan, Jay D Raman, Surena F Matin, Vitaly Margulis,

<h4>Objective</h4>Whether pathologic stage at radical nephroureterectomy (RNU) can serve as an appropriate surrogate for oncologic outcomes in patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) treated with neoadjuvant chemotherapy (NAC) is not defined. We sought to determine whether patients who achieve pathologically non-muscle-invasive (ypT0, ypTa, ypT1, ypTis) HG UTUC ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(12):933.e7-933.e12]

Cited: 0 times

View full text PDF listing >>



Management of Residual or Recurrent Disease Following Thermal Ablation of Renal Cortical Tumors.

Justin Loloi, W Bruce Shingleton, Stephen Y Nakada, Ronald J Zagoria, Jaime Landman, Benjamin R Lee, Surena F Matin, Kamran Ahrar, Raymond J Leveillee, Jeffrey A Cadeddu, Jay D Raman,

Management of residual or recurrent disease following thermal ablation of renal cortical tumors includes surveillance, repeat ablation, or surgical extirpation. We present a multicenter experience with regard to the management of this clinical scenario. Prospectively maintained databases were reviewed to identify 1265 patients who underwent cryoablation (CA) or radiofrequency ablation ... Read more >>

J Kidney Cancer VHL (Journal of kidney cancer and VHL)
[2020, 7(2):1-5]

Cited: 0 times

View full text PDF listing >>



Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.

Nir Kleinmann, Surena F Matin, Phillip M Pierorazio, John L Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott Hubosky, Marcelino Rivera, Michael O'Donnell, Marcus Quek, Jay D Raman, John J Knoedler, Douglas Scherr, Joshua Stern, Christopher Weight, Alon Weizer, Michael Woods, Hristos Kaimakliotis, Angela B Smith, Jennifer Linehan, Jonathan Coleman, Mitchell R Humphreys, Raymond Pak, David Lifshitz, Michael Verni, Mehrad Adibi, Mahul B Amin, Elyse Seltzer, Ifat Klein, Marina Konorty, Dalit Strauss-Ayali, Gil Hakim, Mark Schoenberg, Seth P Lerner,

<h4>Background</h4>Most patients with low-grade upper tract urothelial cancer are treated by radical nephroureterectomy. We aimed to assess the safety and activity of a non-surgical treatment using instillation of UGN-101, a mitomycin-containing reverse thermal gel.<h4>Methods</h4>In this open-label, single-arm, phase 3 trial, participants were recruited from 24 academic sites in the USA ... Read more >>

Lancet Oncol (The Lancet. Oncology)
[2020, 21(6):776-785]

Cited: 5 times

View full text PDF listing >>



Sporadic Angiomyolipomas Growth Kinetics While on Everolimus: Results of a Phase II Trial.

Daniel M Geynisman, Brian T Kadow, Brian M Shuch, Stephen A Boorjian, Surena F Matin, Edward Rampersaud, Barton N Milestone, Elizabeth R Plimack, Matthew R Zibelman, Alexander Kutikov, Marc C Smaldone, David Yt Chen, Rosalia Viterbo, Shreyas Joshi, Richard E Greenberg, Lois Malizzia, Thomas McGowan, Eric A Ross, Robert G Uzzo,

PURPOSE:Everolimus decreases tumor volume of renal angiomyolipomas in patients with tuberous sclerosis. No prospective data are available regarding the effect of everolimus on the growth kinetics in patients with sporadic angiomyolipomas. We sought to determine the safety and efficacy of everolimus in the volumetric reduction of sporadic angiomyolipomas. MATERIALS AND ... Read more >>

J Urol (The Journal of urology)
[2020, 204(3):531-537]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Vitaly Margulis, Maneka Puligandla, Edouard J Trabulsi, Elizabeth R Plimack, Elizabeth R Kessler, Surena F Matin, Guilherme Godoy, Ajjai Alva, Noah M Hahn, Michael A Carducci, Jean Hoffman-Censits, ,

J Urol (The Journal of urology)
[2020, 203(4):697-698]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0423 s